Research Analysts Offer Predictions for Jazz Pharmaceuticals plc’s Q1 2022 Earnings (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) – Research analysts at SVB Leerink raised their Q1 2022 earnings estimates for Jazz Pharmaceuticals in a report released on Thursday, April 21st. SVB Leerink analyst M. Goodman now anticipates that the specialty pharmaceutical company will post earnings of $2.98 per share for the quarter, up from their previous forecast of $2.85. SVB Leerink also issued estimates for Jazz Pharmaceuticals’ Q2 2022 earnings at $3.78 EPS and Q3 2022 earnings at $3.73 EPS.

Several other research analysts have also recently issued reports on the company. StockNews.com upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, April 16th. Cantor Fitzgerald restated an “overweight” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 2nd. Piper Sandler dropped their price target on Jazz Pharmaceuticals from $209.00 to $197.00 and set an “overweight” rating for the company in a research report on Wednesday, March 2nd. BMO Capital Markets dropped their price target on Jazz Pharmaceuticals from $202.00 to $187.00 in a research report on Wednesday, March 2nd. Finally, Royal Bank of Canada dropped their price target on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating for the company in a research report on Wednesday, March 2nd. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $203.92.

Jazz Pharmaceuticals stock opened at $163.00 on Friday. Jazz Pharmaceuticals has a 12 month low of $117.64 and a 12 month high of $189.00. The company has a debt-to-equity ratio of 1.52, a current ratio of 3.23 and a quick ratio of 1.90. The business has a 50 day simple moving average of $154.91 and a 200-day simple moving average of $141.28. The stock has a market capitalization of $10.06 billion, a PE ratio of -29.91, a price-to-earnings-growth ratio of 1.44 and a beta of 0.87.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last posted its quarterly earnings data on Tuesday, March 1st. The specialty pharmaceutical company reported $3.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.98 by $0.68. The business had revenue of $896.73 million during the quarter, compared to the consensus estimate of $866.71 million. Jazz Pharmaceuticals had a positive return on equity of 21.56% and a negative net margin of 10.65%. The company’s revenue was up 34.7% compared to the same quarter last year. During the same period in the prior year, the company earned $3.56 earnings per share.

A number of large investors have recently modified their holdings of JAZZ. Private Capital Group LLC lifted its stake in shares of Jazz Pharmaceuticals by 1,975.0% in the 1st quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 158 shares in the last quarter. Quent Capital LLC acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $31,000. National Bank of Canada FI acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $35,000. CWM LLC acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at about $43,000. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Jazz Pharmaceuticals by 62.8% in the 4th quarter. Itau Unibanco Holding S.A. now owns 609 shares of the specialty pharmaceutical company’s stock valued at $78,000 after purchasing an additional 235 shares in the last quarter. 91.95% of the stock is currently owned by hedge funds and other institutional investors.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 6,372 shares of the firm’s stock in a transaction dated Tuesday, February 1st. The stock was sold at an average price of $139.23, for a total value of $887,173.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 10,772 shares of the firm’s stock in a transaction dated Monday, April 4th. The stock was sold at an average price of $158.33, for a total value of $1,705,530.76. Following the completion of the sale, the chief executive officer now directly owns 346,062 shares in the company, valued at $54,791,996.46. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Read More

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.